Co-Diagnostics, Inc. Files Provisional Patent for Simplified Targeted NGS Library Preparation
Method includes proprietary, single-step closed-tube NGS library prep in 3 hours or less
NGS is a powerful DNA sequencing technology enabling the
mapping or identifying of a large number of DNA fragments
simultaneously. The first stage of the NGS process is the library
preparation, which involves generating a collection of DNA fragments for
sequencing. Co-Diagnostics’ proprietary approach to library preparation
covered under the patent filing is a single-step, closed-tube polymerase
chain reaction (PCR) process taking up to 3 hours with less than 30
minutes of hands-on labor, compatible with existing platforms such as
Ion Torrent and
Company CEO Mr.
“Furthermore, the application of PCR in this manner falls outside of the
definition of an in-vitro diagnostic according to the
Sequencing is used to study a broad spectrum of genetic mutations that might be associated with diseases, or to identify which sequences of a gene that will respond better to certain therapeutics, including cancer genome and individual cancer sequencing to enable more precise diagnoses and personalized treatment. It can be applied to sequencing an entire genome or targeting and sequencing selected regions of interest. Targeted amplicon sequencing allows researchers to sequence a subset of genes or specific genomic regions of interest.
For more information on using this product in your laboratory or
research center, contact
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in liquid biopsy and SNP detection, (iv) use of the Company’s liquid biopsy tests by laboratories, (v) capital resources and runway needed to advance the Company’s products and markets, (vi) increased sales in the near-term, (vii) flexibility in managing the Company’s balance sheet, (viii) anticipation of business expansion, and (ix) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
Head of Investor Relations